{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:39:27Z","timestamp":1781332767015,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijantimicag.2017.01.017","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T17:35:41Z","timestamp":1491327341000},"page":"688-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Jasper","family":"Kamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu S.","family":"Bolhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tiberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Centis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiel C.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G.","family":"Kosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0010","series-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0015","series-title":"Global tuberculosis report","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2013.10.003","article-title":"Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations","volume":"94","author":"Garcia-Prats","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1183\/09031936.00136312","article-title":"Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis","volume":"42","author":"Migliori","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1183\/13993003.01297-2015","article-title":"Tuberculosis elimination, patients' lives and rational use of new drugs: revisited","volume":"47","author":"Tiberi","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.01691-15","article-title":"Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis","volume":"60","author":"Tasneen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0050","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tube.2015.07.003","article-title":"Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates","volume":"95","author":"Zou","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1183\/09031936.00084614","article-title":"Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains","volume":"45","author":"Weiss","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0060","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1128\/AAC.02410-14","article-title":"In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1500286","article-title":"Linezolid for XDR-TB\u2014final study outcomes","volume":"373","author":"Lee","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0075","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1183\/13993003.00606-2015","article-title":"Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study","volume":"46","author":"Bolhuis","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0080","first-page":"1","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0085","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jac\/dks078","article-title":"Daily 300\u2009mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients","volume":"67","author":"Koh","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4046\/trd.2015.78.2.78","article-title":"Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009\u20132014","volume":"78","author":"Ashkin","year":"2015","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0105","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.01194-06","article-title":"Pharmacokinetic\/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model","volume":"51","author":"Boak","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0115","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0120","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0125","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1016\/j.jchromb.2009.08.023","article-title":"Rapid and sensitive liquid chromatography\u2014tandem mass spectrometry method for the determination of linezolid in human serum","volume":"877","author":"Harmelink","year":"2009","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5588\/ijtld.10.0238","article-title":"Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis","volume":"15","author":"Sch\u00f6n","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0135","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1128\/AAC.00757-10","article-title":"Clarithromycin significantly increases linezolid serum concentrations","volume":"54","author":"Bolhuis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0140","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1124\/dmd.106.013755","article-title":"Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients","volume":"35","author":"Plock","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0145","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0150","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.017_bib0155","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:20:27Z","timestamp":1535934027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0924857917301048"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}